Catalysts
Announced deals and their spreads, early takeover signals, biotech dates and the biggest extended-hours moves, in one screen.
8 pending deals25 new 13D stakes5 FDA datesUpdated 11:27 ET
Pending deals
Announced acquisitions of U.S.-listed companies. Spread is the gain to the offer price if the deal closes as agreed. Deals can still break.
BRZEBRZE Braze, Inc.
+4.9%
$45.30
Salesforce Signs Definitive Agreement to Acquire Braze ($47.50 per share in cash)$45.30
CCC CCC Intelligent Solutions Holdi
+1.6%$7.63
MGMG Mistras Group Inc
-5.8%
$21.61
MISTRAS Group, Inc. Enters into Definitive Agreement to Be Acquired by H.I.G. Capital for $20.35 Per Share in Cash$21.61
HHSHHS Harte Hanks, Inc.
+14.7%
$4.36
Harte Hanks Enters Definitive Agreement to Be Acquired by Star Equity Holdings for $5.00 Per Share$4.36
ARX Accelerant Holdings
+2.5%$19.75
Other deal headlines (target or price not parsed)
Takeover watch
Early signals that often come before a deal: sale reports, new 5%+ activist or strategic stakes, and unusual trading volume. Most never turn into a deal.
Sale and buyout reports, last 30 days
CMG Chipotle Mexican Grill, Inc.-0.5%$29.71
SVCSVC Service Properties Trust+1.3%
$6.00
Service Properties Trust Confirms Receipt of Unsolicited Proposal for Hotel Portfolio From TKO Hotels$6.00
ARM Arm Holdings plc-1.9%$223.82
PPC Pilgrim's Pride Corporation-0.4%$28.43
CRBUCRBU Caribou Biosciences, Inc.+5.6%
$0.49
Caribou Shares Fall After Plans to Evaluate Strategic Alternatives, Discontinue CAR-T Programs$0.49
OPCH Option Care Health, Inc.+0.0%$31.22
New SC 13D stakes (SEC), last 3 weeks
SKKSKK SKK Holdings Limited
+11.8%
$6.08
$6.08
TRXBTRXB TRex Bio, Inc.
-0.9%
$14.66
$14.66
LHAILHAI Linkhome Holdings Inc.
+2.1%
$0.83
$0.83
AIOKAIOK AI OKTO CORP.
-0.2%
$4.09
$4.09
TRXBTRXB TRex Bio, Inc.
-0.9%
$14.66
$14.66
TCRTTCRT Alaunos Therapeutics, Inc.
+1.1%
$3.17
$3.17
MXCTMXCT MaxCyte, Inc.
+2.7%
$1.33
$1.33
GGRGGR Gogoro Inc.
+0.0%
$2.96
$2.96
SRTA Strata Critical Medical, Inc.
+2.5%$4.66
TDICTDIC Dreamland Limited
+0.9%
$1.73
$1.73
Unusual volume (last session vs 3-month average)
BRZEBRZE Braze, Inc.
+50.8%
$45.30
Salesforce to Buy Braze for $5.66B, Expanding Real-Time AI Marketing$45.30
MYGNMYGN Myriad Genetics, Inc.
+38.6%
$5.83
Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln$5.83
QRVO Qorvo, Inc.
+0.0%$114.17
LEG Leggett & Platt, Incorporated
-1.3%$9.20
Biotech catalysts
FDA decision (PDUFA) dates and phase 3 readouts. Dates come from company and news headlines plus RTTNews's public FDA calendar; there is no complete free source, so this list is partial.
Upcoming FDA decision dates
Oct 30, 2026 INOINO Inovio Pharmaceuticals, Inc.+3.0%
$1.03
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms$1.03
Jan 28, 2027 
INSM Insmed Incorporated+0.8%
$96.08
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027INSM Insmed Incorporated+0.8%$96.08
Mar 16, 2027 AQSTAQST Aquestive Therapeutics, Inc.+6.7%
$4.08
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027$4.08
Q4 2026 
PFE Pfizer, Inc.+2.2%
$30.09
PFE Pfizer, Inc.+2.2%$30.09
TALZENNA Plus XTANDI (sNDA): FDA decision on TALZENNA in combination with XTANDI for the treatment of metastatic hormone-sensitive prostate cancer
Q4 2026 NVONVO Novo Nordisk A/S+1.9%
$39.15
$39.15
CagriSema (NDA): FDA decision on CagriSema for weight management
Q4 2026 
AZN AstraZeneca PLC+2.7%
$168.30
AZN AstraZeneca PLC+2.7%$168.30
IMFINZI (BLA): FDA decision on IMFINZI plus enfortumab vedotin for muscle-invasive bladder cancer who are ineligible for or have declined cisplatin-based chemotherapy
10/04/2026 Eisai Co Ltd
WELIREG plus LENVIMA (sNDA): FDA decision on WELIREG plus LENVIMA in patients with advanced renal cell carcinoma (RCC)
10/10/2026 
MRK Merck & Company, Inc.+3.1%
$148.09
MRK Merck & Company, Inc.+3.1%$148.09
Ifinatamab deruxtecan (I-DXd) (BLA): FDA decision on ifinatamab deruxtecan for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
10/10/2026 Daiichi Sankyo Company Limited
Ifinatamab deruxtecan (I-DXd) (BLA): FDA decision on ifinatamab deruxtecan for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
Recent FDA decisions
10/04/2026 MRK Merck & Company, Inc.+3.1%
MRK Merck & Company, Inc.+3.1%FDA approved WELIREG plus LENVIMA in patients with advanced renal cell carcinoma on Sep.25, 2026
10/15/2026 Roche Holding AG
FDA approved Enspryng (satralizumab) for the treatment of adults with thyroid eye disease on 16th Oct. 2026.
10/17/2026 IRDIRD Opus Genetics, Inc.+4.1%
FDA approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults on 16th Oct. 2026
10/17/2026 
VTRS Viatris Inc.+1.2%
VTRS Viatris Inc.+1.2%FDA approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults on 16th Oct. 2026
Phase 3 readouts, last 3 weeks
EYPTEYPT EyePoint, Inc.+2.3%
$0.45
EyePoint's Duravyu Misses Primary Endpoint in Second Phase 3 Wet AMD Trial; Shares Fall Pre-Bell$0.45
BIIB Biogen Inc.+4.1%$242.96
CMPS COMPASS Pathways Plc - American+7.1%$11.90
Today's movers
The market is open, so these are regular-session moves. Premarket gaps show here from 4:00 AM ET and after-hours moves from 4:00 PM ET. Extended-hours trading is thin and prices can reverse at the open.
Gapping up
BRZEBRZE Braze, Inc.+50.8%
$45.30
Salesforce to Buy Braze for $5.66B, Expanding Real-Time AI Marketing$45.30
MYGNMYGN Myriad Genetics, Inc.+38.6%
$5.83
Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln$5.83
CTNMCTNM Contineum Therapeutics, Inc.+14.0%
$8.48
Baird Downgrades Contineum Therapeutics to Neutral From Outperform, Price Target is $14$8.48
TRAXTRAX First Tracks Biotherapeutics, I+12.7%
$40.87
First Tracks Biotherapeutics Announces $200 Million Private Placement$40.87
HTZ Hertz Global Holdings, Inc+12.2%$2.06
ORIC Oric Pharmaceuticals, Inc.+12.0%$14.25
EFX Equifax, Inc.+11.7%$177.07
SLSSLS SELLAS Life Sciences Group, Inc+10.8%
$11.62
$11.62
Gapping down
Earnings today: before the open
GE GE Aerospace-3.4%$300.63
RTX RTX Corporation-1.1%$190.01
MMM 3M Company+5.2%$170.47
GM General Motors Company-5.0%$78.58
NOC Northrop Grumman Corporation+4.9%$535.91
MSCI MSCI Inc.+6.1%$597.97
SYF Synchrony Financial-1.2%$73.34
HAL Halliburton Company+1.4%$33.45
Earnings today: after the close
NFLX Netflix, Inc.+0.1%$69.92
ISRG Intuitive Surgical, Inc.+0.5%$435.27
CB Chubb Limited+0.1%$356.56
COF Capital One Financial Corporati+1.1%$201.94
AMXAMX America Movil, S.A.B. de C.V.+0.4%
$22.91
$22.91
UAL United Airlines Holdings, Inc.+3.4%$98.89
EWBC East West Bancorp, Inc.+1.7%$127.66
NLYNLY Annaly Capital Management Inc.+3.0%
$18.25
$18.25
Research only. Not investment advice. Coteau doesn't manage money.
Sources: Yahoo Finance quotes and headlines (delayed), the Coteau news feed, SEC EDGAR full-text search (SC 13D), Nasdaq earnings calendar, RTTNews FDA calendar. Offer prices come from company announcements and headlines; when a price can't be read it's left blank. Refreshed every 15 minutes on weekdays.
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.